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Introduction: ATP-binding cassette (ABC) transporters are a group of intra membrane 
proteins that play key roles in the transmission and exchange of vital compounds on both 
sides of the membrane. These proteins can specially transport anti-cancer drugs out of cancer 
cells. ABCG2 is a member of this family that is extremely expressed in many cancers. This 
study, aims to evaluate the binding affinity of three antioxidants thymoquinone (TQ), gallic 
acid (GA), and hesperetin (HP) to ABCG2 compared with an anti-cancer drug, mitoxantrone 
(Mit), to export cells.
Methods: The PDB file of ABCG2 was obtained from the protein data bank server (http://
www.rcsb.org) with ID: 5NJ3. After 200 stages of molecular docking running on ABCG2 
protein in AutoDock v.4.2 software, the amino acids involved in the binding site of each 
compound were identified using the LigPlot+ software.
Results: HP had the lowest (-6.36 kcal/mol) and GA had the highest (-3.93 kcal/mol) 
binding energy in comparison with Mit (-0.06 kcal/mol) for binding to ABCG2. Effective 
concentration required to perform the reaction between ABCG2 was higher in GA (1.31 mM) 
than TQ (42.69 µM) and HP (21.74 µM). GA, HP, and TQ formed 17, 18, and 22 hydrogen and 
hydrophobic bonds at the binding site of ABCG2.
Conclusion: It seems that GA has the lowest affinity to make contact with ABCG2 binding 
site. So, GA tends to remain in the cell but TQ and HP tend to leave the cell easily via ABCG2 
transporter.
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A B S T R A C T
Introduction
ATP-binding cassette (ABC) transporters are a family of 
proteins that are present in cell membrane and play key 
roles in the transport of vital compounds out of the cells (1). 
There are 48 ABC transporter proteins, known in human 
body cells, which are divided into seven subgroups of ABC 
(A-G) based on their size, number of subunits and their 
building (2,3). Any malfunctioning of these membrane 
proteins causes a variety of diseases and the occurrence of 
mutations in the building of these molecules also causes 
genetic disorders such as cystic fibrosis (4), gout (5) and 
lipid metabolic abnormalities (6). Today, the importance 
of these membrane transporters has increased due to 
their role in resistance to anticancer drugs that cause the 
drug to escape from the cell before it exerts its effect (7). 
ABCG2 transporters are of the most important members 
of this great family. They exist and have physiological roles 
in many tissues, such as breast, brain, and testicular, as 
well as in many cancers, especially breast cancer, stomach 
cancer, and pancreatic cancer (8-10). The most important 
http://www.herbmedpharmacol.com doi: 10.15171/jhp.2019.17
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physiological role of ABCG2 transporter is the transfer of 
uric acid. Any disruption in the normal functioning of 
this protein causes diseases such as gout, hypertension, 
and kidney disorders (11). In addition, its expression 
is increased in many cancers and can be recognized as 
a marker of cancer at the cell surface. However, it is a 
proprietary marker for hematopoietic stem cells (12). 
ABCG2 as an intracellular drug transporter, causes the 
drug resistance in cancer cells (13). Despite significant 
advances in the treatment of various types of cancers, 
there is still an increasing incidence of cancer in different 
societies (14,15). On the other hand, studies have shown 
that herbal compounds play a very important role in the 
death of different types of cancer cells (16). Hesperetin 
(HP) or 2,3-Dihydro-5,7-dihydroxy-2- (3-hydroxy-4-
methoxyphenyl)-4H-1 benzopyran-4-one), gallic acid 
(GA) or 3,4,5-trihydroxybenzoic acid and thymoquinone 
(TQ) or 2-Isopropyl-5-methylbenzo-1,4-quinone (17,18) 
are effective compounds found in plants such as onion, 
apple, green and black tea, red grapes, citrus, broccoli 
sprouts, tomato (19) and in some fruits like berries and 
grapes, hard wood plant species such as chestnut (Castanea 
sativa L.) and oak (Quercus robur), and also in tea (20) 
and Nigella sativa Linn (21). Many studies have shown 
that these three active plant compounds are very effective 
in destroying cancer cells, especially gastric cancer cells 
(22-24). Because of the importance of ABC transfer 
proteins in cancer cells, especially gastric cancer cells, 
as well as the confirmation of the effects of HP, GA, and 
TQ antioxidants on cell death in gastric cancer cells. This 
study, was designed to evaluate the effects of these three 
antioxidants on ABCG2 transporter using simulation and 
molecular docking and measuring the tendency of this 
protein to remove these three plant compounds from the 
cell, compared to anticancer drug, mitoxantrone (Mit).
Materials and Methods
We obtained the ABCG2 PDB file (ID: 5NJ3) from protein 
data bank server (http://www.rcsb.org) and optimized 
with Arguslab v.4.0 software. Then, we obtained the 
antioxidant files of GA (CID:370), HP (CID: 72281), and 
TQ (CID:10281) from Pubchem server and converted 
them to PDB files and optimized using Arguslab v.4.0 
software (25).
Molecular docking studies were done by Autodock v.4.2 
software in Linux operating system by a 64-bit system 
with Intel® CoreTM i7 CPU Server in Clinical Biochemistry 
Research Center, Basic Health Sciences Institute of 
Shahrekord University of Medical Sciences.
Molecular docking of GA, HP, and TQ on ABCG2 
transporter was done to find the best binding sites for 
the ligand-receptor and to determine the most stable free 
energy state of ligand-receptor. In this study, we built a 
Grid Box with 60×120×72 nm (x×y×z) for intra cellular 
NBD domains, after the production of PDBQ and PDBQT 
files of TQ, GA, and HP as ligands and ABCG2 transporter 
as receptor. We used autogrid 4 –p n.gpf –l n.gle linux in 
order to produce the n.gle text file. After 200 stages of 
molecular docking running on ligands, we used genetic 
algorithm (GA) and Lamarckian GA parameters. To 
produce the n.dlg text file, we used autodock 4 –p n.dpf –l 
n.dlg linux order. The data obtained from n.dlg file, were 
analyzed (26).
In this study, we used LigPlot+ software to specify the 
number of hydrophobic and hydrogen bonds between 
ABCG2 transporter and GA, TQ, and HP ligands and the 
type and number of amino acids present in the binding 
site were identified (27).
Results
Figure 1 shows the structure of ABCG2 transporter 
and three antioxidants HP, GA, and TQ. In this figure, 
nucleotide binding domains (NBDs) in intra cellular 
membrane and transmembrane domains (TMDs) in extra 
cellular membrane were visible.
Table 1 shows the molecular interaction and the binding 
energies of Mit, GA, HP, TQ, with ABCG2. After Mit, the 
estimated binding free energy (BE) for GA was higher 
than HP and TQ. Estimated inhibition constant (EIC) for 
GA was lower than HP and TQ.
Figure 2 shows that the interaction between ABCG2 
with TQ has the most hydrogen and hydrophobic 
bonds and after the interaction between ABCG2 with 
Mit, interaction between ABCG2 with GA has the least 
hydrogen and hydrophobic bonds.
Discussion
The potential of stem cells in the tissues and the ability 
to differentiate into somatic cell types have played very 
important roles in the reconstruction of damaged tissue 
parts (28,29). Cancer stem cells (CSCs), which in many 
Figure 1. The structure of molecules. ABCG2 transporter with nucleotide 
binding domains (NBDs) and transmembrane domains (TMDs). HP: 
hesperetin, GA: gallic acid, TQ: thymoquinone, Mit: mitoxantrone.
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cases originate from stem cells, also behave like stem cells. 
They have the ability to grow, replicate, and differentiate 
into other cancer cell lines (30-33). However, studies have 
shown that, at the CSCs surface, cell-specific markers 
increase expression, which can be specific for each cell line. 
For example, in GCSC cells, ABCB1 cell markers, CD133, 
ABCG2, are strongly expressed (9). Increase in expression 
of ABC carriers induces a unique feature in GCSC cells, 
which makes them resistant to chemotherapy (34). 
Nowadays, the structure and function of ABC transporter 
proteins are well known. This family of proteins consists 
of two domains, NBDs with ATPase activity inside the cell 
and two TMDs attached to the outer membrane (35,36). 
Our study well illustrated that the ABCG2 transporter had 
a great ability to convey different compounds out of the 
cell. The strong tendency of GA, TQ, and QC toward the 
binding site in the NBD domains represents a tendency for 
this transition. Recent studies have shown that the amino 
acid E446 in NBD domain of ABCG2 transfer, plays an 
important role in the transfer of drugs to the outside of 
Table 1. Molecular docking parameters between ABCG2 transporter and other ligands
Interaction bonds
EIC FIE BE Ligands
Hydrophobic Bonding Hydrogen Bonding
Val1802, Ser1803, Leu1804, Gly1805, 
Asp1806 Val1802, Ser1803, Leu1804, Gly1805, Asp1806 900.1 mM -4.48 0.06- Mit
Asp419, Tyr1462, Arg1403, Phe1262, 
Gly1264, Tyr 1166, Thr1465
Ser420, Trp1463, Asn1165, Asp419, Tyr1462, 
Arg1403, Phe1262, Gly1264, Tyr 1166, Thr1465 1.31 mM -5.72 -3.93 GA
Gln1584, Gln1692, Asn1831, Lys1828, 
Arg1834, Ala1832, Tyr1689, Leu1585, 
Trp1690
Gln1584, Gln1692, Asn1831, Lys1828, Arg1834, 
Ala1832, Tyr1689, Leu1585, Trp1690 21.74 µM -6.96 -6.36 Hp
Tyr51, Ser420, Asn1165, Asn419, Trp1467, 
Thr1465, Pro593, Tyr1462, Trp1463, 
Arg1403, Tyr1166
Tyr51, Ser420, Asn1165, Asn419, Trp1467, 
Thr1465, Pro593, Tyr1462, Trp1463, Arg1403, 
Tyr1166
42.69 µM -6.26 -5.96 TQ
Abbreviations: BE, Estimated Free Energy of binding (kcal/mol); FIE, final intermolecular energy (kcal/mol); EIC, estimated inhibition constant; Mit, 
mitoxantrone; GA, gallic acid; HP, hesperetin; TQ, thymoquinone.
Figure 2. Interaction bonds such as hydrogen and hydrophobic bonds between ABCG2 with Mit, GA, HP and TQ. Mit, mitoxantrone; GA, gallic acid; HP, 
hesperetin; TQ, thymoquinone.
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the cell as well as the ATPase property of this transporter. 
So that the removal of any of the E466K, E451R, E458R 
D477R amino acids causes a disruption of protein function 
and the deficiency of efflux of the drug Mit from cell. 
Also, K647, K652, K653 amino acids in the TMD domain 
interact with cellular membrane phospholipids electro 
statically, which stabilizes the protein and binds to the cell 
membrane. However, they don’t have a significant role 
in the efflux of Mit drug (37). Other studies have shown 
that the amino acid K473 plays an important role in the 
formation and deployment of monomers alongside each 
other (38-40). The ABCG2 transporter plays an important 
role in the efflux of cholesterol from the cell. Taylor et al. 
showed that six amino acids F432, F439, L539, I543, V546, 
and M549 play a key role in connecting two cholesterol 
molecules to the ABCG2 molecule (41). The fluorescent 
dyes Hoechst 33342 and rhodamine123 (R123) are desire 
substrates for the ABCG2 and ABCB1 transporters, 
respectively (42). In our study, Figure 2 and Table 1 show 
that anti-drug cancer Mit, just interacted with five amino 
acids (Val1802, Ser1803, Leu1804, Gly1805, Asp1806) in 
binding site. However, the highest amount of estimated 
binding free-energy (BE) was -0.06 kJ/mol and the highest 
EIC was 900.1 mM. This indicates that the rate at which 
Mit binds to the binding site in the ABCG2 molecule is 
very low and the possibility of efflux of this drug from the 
cell by this transporter is very low. In addition, in order to 
allow this connection to be thermodynamically applicable, 
the Mit concentration of the cell should reach 900.1 mM. 
This concentration of drug is very high. However, at 
much lower concentrations, the drug can play its role in 
the treatment process in cancer cells. Many studies have 
shown that GA is a powerful antioxidant compound in the 
death of cancer cells (43,44).
Based on the results in Figure 2 and Table 1, GA interacts 
with amino acids in binding site by ten hydrogen bonds 
and six hydrophobic bonds. Its BE was -3.93 kcal/mol and 
its EIC was 1.31 mM. These amounts are lower than the 
amounts obtained from Mit connection with the binding 
site. However, compared to the two anti-oxidants, HP and 
TQ are much higher, such that HP and TQ had 18 and 22 
interaction bonds with ABCG2 and their BE were -6.96 
and -6.36 kcal/mol. HP and TQ with lower concentrations 
of 21.74 and 42.69 µM were in contact with ABCG2. This 
indicates that they tend to efflux the cell. Previous studies 
have shown that the IC50 concentrations of these three 
antioxidant compounds are different for the induction 
of anticancer effects in different cancer cells. The lowest 
IC50 has been obtained in comparison with HP and TQ 
for the GA molecule (25,45,46). This can be a reason for 
the results obtained in this study. Our study showed that 
GA compared to other two compounds could be more 
resistant to low concentrations in cancer cells, hence, it 
exerts its anticancer effects, while two other drugs (TQ 
and HP) need to use much higher concentrations, which 
can have toxic effect on other cells.
Conclusion
Although antioxidant compounds can inhibit cancer cells 
and induce cancer cell death, but proprietary transponders, 
such as ABCG2, discard these compounds and other anti-
cancer drug compounds from cancer cells. This study 
showed that GA, compared with TQ and HP by a very low 
binding affinity with these membrane transfer proteins, 
could have longer existence in the cell, and would have a 
higher effect on the removal of cancer cells.
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